Clinical trials: Metabolism and Elimination
Advanced Solid Malignancies
Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg dose of TKI258 followed after 15 days by daily…
- Trial name
- NCT00669097
- Testing
- TKI258
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
The purpose of this study is to describe the single dose pharmacokinetics of total radioactivity in plasma and whole blood following PO administration of [14C] TR-701 in healthy adult male subjects.
- Trial name
- NCT01442831
- Testing
- Human ADME
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy
Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects
This will be a Phase 1, open-label, nonrandomized, single-dose study in healthy male subjects to evaluate the Absorption, Metabolism, and Excretion of Poziotinib following a single oral dose of [14C]-poziotinib to healthy male…
- Trial name
- NCT04436562
- Testing
- [14C]-Poziotinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Spectrum Pharmaceuticals, Inc
Healthy Volunteers
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
- Trial name
- NCT06433505
- Testing
- BMS-986365, [14C] BMS-986365, [14C] BMS-986409 + BMS-986410
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Carcinoid Syndrome
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.
- Trial name
- LX1606-104 (NCT01932528)
- Testing
- 500 mg [14C]-LX1606
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Healthy
A Study of [14C]-LY4065967 in Healthy Participants
The purpose of this study is to investigate the absorption, metabolism, excretion, and bioavailability of LY4065967 in healthy male participants. This is a 2-part study.
- Trial name
- NCT07039045
- Testing
- LY4065967, [14C]-LY4065967 Oral, [14C]-LY4065967 IV
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058
the purpose of this study is: to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7…
- Trial name
- ADME (NCT04991181)
- Testing
- 400 mg BIA 5-1058
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Men and Women
Absorption, Metabolism and Excretion of Artichoke Polyphenols in Healthy Individuals
A number of studies have reported the presence of polyphenolic compounds in artichokes, being the most abundant the caffeoylquinic acids (CQAs), which are esters between quinic acid and the hydroxycinnamate caffeic acid.
- Trial name
- NCT04095949
- Testing
- Artichokes
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- King's College London
Healthy
Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose
The study is designed to investigate the absorption, metabolism, and excretion of EYP001a as well as the safety/tolerability of EYP001a following the administration of a single oral dose to healthy male volunteers.
- Trial name
- NCT04037618
- Testing
- [14C]-EYP001a
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Healthy Volunteers
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
- Trial name
- NCT06281158
- Testing
- [14C]-DNL343
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Denali Therapeutics Inc.
Healthy Volunteer Study
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
Mass balance study of AT-527 in Healthy Male Subjects.
- Trial name
- NCT05004415
- Testing
- AT-527 (R07496998)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Healthy Volunteer
A Study to Learn How ASP3082 is Processed in Healthy Men
Setidegrasib (ASP3082) is being developed for certain cancers. In this study, the researchers want to understand how it is processed by the body in healthy male volunteers.
- Trial name
- NCT07773129
- Testing
- 14C-labeled ASP3082
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Type 1 Diabetes
PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who…
- Trial name
- PREVENTKD (NCT00729365)
- Testing
- Ramipril
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Northwestern University
Healthy Male Volunteers
Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-20 mg/100 μCi Anaprazole Sodium Enteric-coated Capsule in Healthy Adult Male Subjects
This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single oral dose of [14C]-20 mg/100 μCi Anaprazole Sodium enteric-coated capsule in healthy adult male subjects.
- Trial name
- NCT04476394
- Testing
- [14C]-Anaprazole Sodium enteric-coated capsule
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Diabetes Mellitus, Type 2
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of…
- Trial name
- NCT00229684
- Testing
- Tesaglitazar, pioglitazone
- Where
- 21 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Insomnia
A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers
To determine the mass balance of PD 0200390
- Trial name
- NCT00722306
- Testing
- PD 0200390
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study in Healthy Men to Test How BI 1584862 is Processed in the Body
The goal of this study is to find out how BI 1584862 moves through and exits the body of healthy men. To do this, BI 1584862 is labelled using radioactive carbon (C-14) and using a non-radioactive, naturally occurring, stable…
- Trial name
- NCT07336758
- Testing
- [13C]-labeled BI 1584862, Unlabeled BI 1584862 mixed with [14C]-labeled BI 1584862
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type II Diabetes
Mass Balance and Biotransformation of [14C]HSK7653 in Human
A single-center, single-dose, non-randomized, open-label design.
- Trial name
- NCT04540016
- Testing
- [14C]HSK7653
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Healthy Volunteers
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of [14C]-CC-92480 and to evaluate the safety and…
- Trial name
- NCT04560738
- Testing
- [14C]-CC-92480
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Volunteers
A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants
The purpose of the study is to determine absorption, metabolism, and excretion of a single oral dose of [14C]-xevinapant. This information will enable assessment of absorption and clearance mechanisms of [14C]-xevinapant as well…
- Trial name
- NCT04962724
- Testing
- Radiolabelled Xevinapant 200 mg (Oral Solution), Radiolabelled Xevinapant 100 μg (IV Solution), Xevinapant 200 mg (Oral Solution)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Debiopharm International SA